HNB
ACAD icon

Huntington National Bank’s Acadia Pharmaceuticals ACAD Stock Holding History

Huntington National Bank’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12
Closed -$199 – 4148
2025
Q1 		$199 Buy
+12
New +$218 ﹤0.01% 2633
2024
Q3 		– Sell
-50
Closed -$813 – 4147
2024
Q2 		$813 Hold
50
– – ﹤0.01% 2345
2024
Q1 		$925 Buy
+50
New +$1.24K ﹤0.01% 2293
2020
Q2 		– Sell
-1,025
Closed -$43K – 1477
2020
Q1 		$43K Hold
1,025
– – ﹤0.01% 823
2019
Q4 		$44K Buy
+1,025
New +$44.6K ﹤0.01% 986
2019
Q1 		– Sell
-100
Closed -$2K – 1525
2018
Q4 		$2K Buy
+100
New +$1.94K ﹤0.01% 1549
2016
Q4 		– Sell
-27
Closed – – 1427
2016
Q3 		$0 Hold
27
– – ﹤0.01% 1516
2016
Q2 		$0 Sell
27
-49
-64% -$1.64K ﹤0.01% 1482
2016
Q1 		$2K Buy
76
+3
+4% +$65 ﹤0.01% 1636
2015
Q4 		$3K Sell
73
-5
-6% -$176 ﹤0.01% 1523
2015
Q3 		$3K Buy
78
+7
+10% +$291 ﹤0.01% 1582
2015
Q2 		$3K Sell
71
-5
-7% -$194 ﹤0.01% 1648
2015
Q1 		$2K Sell
76
-31
-29% -$1.07K ﹤0.01% 1647
2014
Q4 		$3K Buy
+107
New +$3.03K ﹤0.01% 1583

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Huntington National Bank's ACAD Position: Q2 2025 in Review

Huntington National Bank sold out of Acadia Pharmaceuticals (ACAD) in Q2 2025, closing a stake of 12 shares — an estimated $199 sold.

Huntington National Bank first reported a position in ACAD in Q4 2014 and held it in 14 quarters. The position peaked at $44K in Q4 2019. 310 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.

  • Huntington National Bank reported no remaining Acadia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Huntington National Bank sold 12 Acadia Pharmaceuticals shares in Q2 2025, an estimated $199.
  • Huntington National Bank first reported a position in Acadia Pharmaceuticals in Q4 2014 and held it in 14 quarters.
  • Huntington National Bank's Acadia Pharmaceuticals position peaked at $44K in Q4 2019.
  • 310 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.

Based on Huntington National Bank's 13F filing for Q2 2025, filed 5 Aug 2025.